Pittenger & Anderson Inc. Buys 304 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Pittenger & Anderson Inc. increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,167 shares of the medical research company’s stock after purchasing an additional 304 shares during the period. Pittenger & Anderson Inc.’s holdings in Thermo Fisher Scientific were worth $15,568,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. W.H. Cornerstone Investments Inc. boosted its holdings in Thermo Fisher Scientific by 4.7% in the third quarter. W.H. Cornerstone Investments Inc. now owns 2,294 shares of the medical research company’s stock valued at $1,419,000 after acquiring an additional 104 shares during the last quarter. Sentry Investment Management LLC lifted its position in Thermo Fisher Scientific by 7.5% during the 3rd quarter. Sentry Investment Management LLC now owns 2,641 shares of the medical research company’s stock valued at $1,634,000 after purchasing an additional 185 shares during the period. United Advisor Group LLC grew its position in shares of Thermo Fisher Scientific by 55.4% during the 3rd quarter. United Advisor Group LLC now owns 701 shares of the medical research company’s stock worth $434,000 after buying an additional 250 shares during the period. ASB Consultores LLC lifted its holdings in Thermo Fisher Scientific by 34.5% in the third quarter. ASB Consultores LLC now owns 1,056 shares of the medical research company’s stock valued at $653,000 after buying an additional 271 shares during the period. Finally, Martin Investment Management LLC grew its holdings in Thermo Fisher Scientific by 1.1% during the 3rd quarter. Martin Investment Management LLC now owns 17,038 shares of the medical research company’s stock worth $10,539,000 after acquiring an additional 190 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $554.29, for a total value of $5,542,900.00. Following the transaction, the chief executive officer now directly owns 121,192 shares of the company’s stock, valued at $67,175,513.68. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $554.29, for a total value of $5,542,900.00. Following the completion of the sale, the chief executive officer now owns 121,192 shares of the company’s stock, valued at approximately $67,175,513.68. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 5,850 shares of the firm’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $557.89, for a total transaction of $3,263,656.50. Following the transaction, the chief executive officer now directly owns 121,192 shares in the company, valued at approximately $67,611,804.88. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 18,150 shares of company stock worth $10,094,925. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.4 %

TMO opened at $555.47 on Tuesday. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The stock’s fifty day simple moving average is $598.39 and its 200 day simple moving average is $583.86. Thermo Fisher Scientific Inc. has a 1-year low of $437.26 and a 1-year high of $627.88. The stock has a market cap of $212.19 billion, a PE ratio of 34.83, a price-to-earnings-growth ratio of 3.69 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. The company had revenue of $10.60 billion during the quarter, compared to analysts’ expectations of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. Thermo Fisher Scientific’s quarterly revenue was up .2% compared to the same quarter last year. During the same quarter last year, the company posted $5.69 EPS. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Barclays reduced their price target on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. Bernstein Bank boosted their target price on Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research report on Tuesday, October 22nd. Raymond James lifted their price objective on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Stifel Nicolaus lowered their target price on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. Finally, Redburn Atlantic assumed coverage on shares of Thermo Fisher Scientific in a report on Monday, October 14th. They issued a “buy” rating and a $680.00 price target for the company. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $649.33.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.